HomePress-release

Redding, California - July 9, 2024

Recombinant Coagulation Factors Market to be Worth $26.29 Billion by 2031

Recombinant Coagulation Factors Market Size, Share, Forecast, & Trends Analysis by Type (Factor VIII, Factor IX), Source (CHO, HEK), Application (Hemophilia (Type A, Type B), Others), End User (Hospitals, CRO) - Global Forecast to 2031

Meticulous Research^®—a leading global market research company, published a research report titled ‘Recombinant Coagulation Factors Market Size, Share, Forecast, & Trends Analysis by Type (Factor VIII, Factor IX), Source (CHO, HEK), Application (Hemophilia (Type A, Type B), Others), End User (Hospitals, CRO) - Global Forecast to 2031.’

According to this latest publication from Meticulous Research^®, the recombinant coagulation factors market is projected to reach $26.29 billion by 2031, at a CAGR of 8.6% during the forecast period. The increasing prevalence of hemophilia and other bleeding disorders, growing R&D for coagulation factors, growing awareness about the benefits of the recombinant coagulation factors, and increasing prophylactic treatment for hemophilia across the globe are driving the growth of the recombinant coagulation factors market. However, the high cost of recombinant factors compared to plasma-derived factors and the limited accessibility & availability of recombinant clotting factors in developing & underdeveloped countries are expected to restrain the growth of this market.

Furthermore, untapped markets in emerging economies and rising healthcare expenditure are expected to create market growth opportunities. However, challenges in the production of recombinant coagulation factors, stringent regulatory requirements, lack of reimbursement in some countries, and lack of awareness among patients are some of the challenges impacting the market’s growth.

Recombinant Coagulation Factors Market: Future Outlook

The recombinant coagulation factors market is segmented based on Type (Recombinant Factors VIII, Recombinant Factor IX, and Other Types), Source (Chinese Hamster Ovary (CHO) Cell Line, Human Embryonic Kidney (HEK) Cell Line, and Other Sources), Application (Hemophilia A, Hemophilia B, and Other Applications), End User (Hospitals & Clinics and Clinical Research Laboratories), and Geography. The study also evaluates industry competitors and analyzes the market at the regional and country levels.

Based on type, in 2024, the recombinant factor VIII segment is expected to account for the largest share of 59.5% of the recombinant coagulation factors market. This segment's large market share is attributed to the rising prevalence of bleeding disorders, the high efficacy of recombinant factor VIII, and the higher adoption compared to other types due to the well-established presence of recombinant factor VIII in the market since 1992.

Based on source, the recombinant coagulation factors market is segmented into Chinese hamster ovary (CHO) cell line, human embryonic kidney (HEK) cell line, and other sources. In 2024, the Chinese hamster ovary (CHO) cell line segment is expected to account for the largest share of the recombinant coagulation factors market. The large market share of this segment is attributed to the higher utilization of CHO cell lines and their advantages, such as the ability to generate glycosylation profiles of humankind, high reproducibility, and easy manipulation.

Based on application, the recombinant coagulation factors market is segmented into hemophilia A, hemophilia B, and other applications. In 2024, the hemophilia A segment is expected to account for the largest share of 64.3% of the market. The large share of this segment is attributed to the high prevalence of hemophilia A, the rising adoption of recombinant coagulation factors for the treatment of hemophilia A, and increased patient awareness about the disease.

Based on end user, the recombinant coagulation factors market is segmented into hospitals & clinics and clinical research laboratories. In 2024, the hospitals & clinics segment is expected to account for the larger share of this market. The large market share of this segment is attributed to the high utilization of recombinant coagulation factors in hospitals & clinics and increased awareness among healthcare professionals regarding advanced treatment options.

Geographic Review

This research report analyzes major geographies and provides comprehensive market insights into the market in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Netherlands, Sweden, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa.

In 2024, North America is expected to account for the largest share of 43.4% of the recombinant coagulation factors market, followed by Europe and Asia-Pacific. Furthermore, in 2024, the U.S. is expected to account for the largest share of the North America market. North America’s significant market share can be attributed to its well-established healthcare infrastructure, high patient awareness about recombinant coagulation factors for the treatment of coagulation disorders, high R&D expenditure, and high favorable reimbursement scenarios.

Key Players

The key players operating in the recombinant coagulation factors market are Baxter International Inc. (U.S.), Grifols, S.A. (Spain), CSL Limited (Australia), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen Inc. (U.S.), Bayer AG (Germany), Kedrion S.p.A. (Italy), Emergent BioSolutions (U.S.), and Pfizer Inc. (U.S.).

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=1254

Key Questions Answered in the Report:

Which are the high-growth market segments in terms of type, source, application end user, and region/country?
What was the historical market size for recombinant coagulation factors across the globe?
What are the market forecasts and estimates for the period 2024–2031?
What are the major drivers, restraints, and opportunities in the global recombinant coagulation factors market?
Who are the major players in the global recombinant coagulation factors market?
What is the competitive landscape like?
What are the recent developments in the recombinant coagulation factors market?
What are the different strategies adopted by the major players in the recombinant coagulation factors market?
What are the geographical trends and high-growth regions/countries?

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

3D Printing

5G Technology

Advanced Chemical & Materials

Agrochemicals

Algae Products

Alternative Proteins

Animal Health

Artificial Intelligence

Automotive Technologies

Big Data Analytics

Climate Technologies

Edible Insects

Electric Vehicle

Food & Agriculture Technologies

Hydrogen Technologies

Internet Of Things

In Vitro Diagnostics

Laboratory Instrumentation

Language Learning Technologies

Medical Technologies

Next Generation Technologies

Processing & Packaging Technologies

Robotics & Automation

Smart Technologies

Water & Wastewater Technologies

Miscellaneous / Others

Redding, California - July 9, 2024

Recombinant Coagulation Factors Market to be Worth $26.29 Billion by 2031

Recombinant Coagulation Factors Market Size, Share, Forecast, & Trends Analysis by Type (Factor VIII, Factor IX), Source (CHO, HEK), Application (Hemophilia (Type A, Type B), Others), End User (Hospitals, CRO) - Global Forecast to 2031

Recommended Readings

Advanced Chemical &
Materials

Food & Agriculture
Technologies

Next Generation
Technologies

Processing & Packaging
Technologies

Water & Wastewater
Technologies